Clinical Trials
29 trialsNCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05180006 2025-12-01
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Terminated
NCT00520975 2025-03-28
Bevacizumab in Treating Patients With Metastatic Breast Cancer That Overexpresses HER-2/NEU
National Cancer Institute (NCI)
Phase 3 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT00679029 2023-12-11
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Phase 2 Terminated
NCT00925652 2022-01-19
ABCDE
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT00461773 2021-03-16
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
Yale University
Phase 2 Terminated
NCT00536939 2020-09-24
Trial of Paclitaxel, Bevacizumab, and Enzastaurin Versus Paclitaxel, Bevacizumab and Placebo for Breast Cancer
Eli Lilly and Company
Phase 2 Terminated
NCT00625898 2020-09-10
BETH
NSABP Foundation Inc
Phase 3 Terminated
NCT00281528 2019-11-22
Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer
Celgene
Phase 2 Terminated
NCT00462865 2019-04-09
Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse
Brown University
Phase 2 Terminated
NCT00979641 2019-03-28
AINO
Tampere University Hospital
Phase 2 Terminated
NCT01690325 2018-08-13
Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)
West German Study Group
Phase 2 Terminated
NCT00632541 2018-02-14
A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer
Hoosier Cancer Research Network
Phase 2 Terminated
NCT02250118 2017-11-06
BEVAP
Institut Curie
Phase 1 Terminated
NCT01120158 2017-02-23
Paclitaxel Plus Bevacizumab for Older Patients With Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00537173 2017-01-25
Predicting Response and Toxicity in Patients Receiving Paclitaxel and Avastin for Breast Cancer
Hoosier Cancer Research Network
Terminated
NCT00845910 2016-11-02
A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT01069796 2016-03-17
Bevacizumab + Paclitaxel + Capecitabine in Triple Negative Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
Phase 2 Terminated
NCT00356681 2015-10-15
A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer
Amgen
Phase 2 Terminated
NCT01985841 2015-10-08
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00694200 2015-05-29
Vinorelbine Metronomic Plus Bevacizumab as Salvage Therapy for Breast Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00576901 2014-08-11
A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Docetaxel in Patients With Inflammatory or Locally Advanced Breast Cancer.
Hoffmann-La Roche
Phase 2 Terminated
NCT00674011 2014-05-06
Hypertension in Breast Cancer Patients Receiving Bevacizumab
Dana-Farber Cancer Institute
Terminated
NCT00517361 2014-04-15
Phase II Study of Carboplatin and Bevacizumab (Avastin) for ER Neg, PR Neg, and HER2/Neu Neg Metastatic Breast Cancer
University of Chicago
Phase 2 Terminated
NCT00476827 2013-07-17
A Phase II Safety and Tolerability Study of Bevacizumab When Added to Single-agent Chemotherapy to Treat Patient With Breast Cancer Metastatic to Brain
Duke University
Phase 2 Terminated
NCT01200212 2013-05-22
TABEA
GBG Forschungs GmbH
Phase 3 Terminated
NCT00523809 2013-01-28
Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00434356 2009-12-03
A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)
Genentech, Inc.
Phase 2 Terminated